Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers

BACKGROUND: It is unclear whether generics are as safe as brand-name drugs in cardiology. For public health surveillance purposes, we evaluated if switching from the brand-name losartan, valsartan, or candesartan impacted the occurrence of the following outcomes: emergency room (ER) consultations, h...

Descripción completa

Detalles Bibliográficos
Autores principales: Leclerc, Jacinthe, Blais, Claudia, Rochette, Louis, Hamel, Denis, Guénette, Line, Beaudoin, Claudia, Poirier, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221012/
https://www.ncbi.nlm.nih.gov/pubmed/32342284
http://dx.doi.org/10.1007/s40268-020-00307-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221012/
https://www.ncbi.nlm.nih.gov/pubmed/32342284
http://dx.doi.org/10.1007/s40268-020-00307-2

Ejemplares similares